CA2534292A1 - Substituted imidazopyrimidines for the prevention and treatment of cancer - Google Patents

Substituted imidazopyrimidines for the prevention and treatment of cancer Download PDF

Info

Publication number
CA2534292A1
CA2534292A1 CA002534292A CA2534292A CA2534292A1 CA 2534292 A1 CA2534292 A1 CA 2534292A1 CA 002534292 A CA002534292 A CA 002534292A CA 2534292 A CA2534292 A CA 2534292A CA 2534292 A1 CA2534292 A1 CA 2534292A1
Authority
CA
Canada
Prior art keywords
pyrimidine
imidazo
methylsulfanylphenyl
nmr
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002534292A
Other languages
English (en)
French (fr)
Inventor
Juan Lorenzo Catena Ruiz
Carles Farrerons Gallemi
Anna Fernandez Serrat
Carmen Serra Comas
Dolors Balsa Lopez
Carmen Lagunas Arnal
Carolina Salcedo Roca
Andres Fernandez Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Salvat SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2534292A1 publication Critical patent/CA2534292A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002534292A 2003-07-30 2004-07-29 Substituted imidazopyrimidines for the prevention and treatment of cancer Abandoned CA2534292A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200301906 2003-07-30
ES200301906 2003-07-30
PCT/EP2004/008476 WO2005014598A1 (en) 2003-07-30 2004-07-29 Substituted imidazopyrimidines for the prevention and treatment of cancer

Publications (1)

Publication Number Publication Date
CA2534292A1 true CA2534292A1 (en) 2005-02-17

Family

ID=34130555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002534292A Abandoned CA2534292A1 (en) 2003-07-30 2004-07-29 Substituted imidazopyrimidines for the prevention and treatment of cancer

Country Status (14)

Country Link
US (1) US20060189631A1 (https=)
EP (1) EP1660500B1 (https=)
JP (1) JP2007500160A (https=)
KR (1) KR20060034303A (https=)
CN (1) CN1860121A (https=)
AT (1) ATE380816T1 (https=)
AU (1) AU2004263297A1 (https=)
BR (1) BRPI0412636A (https=)
CA (1) CA2534292A1 (https=)
DE (1) DE602004010680T2 (https=)
EA (1) EA009038B1 (https=)
ES (1) ES2298798T3 (https=)
WO (1) WO2005014598A1 (https=)
ZA (1) ZA200601706B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096764A2 (en) * 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
EP2062893A1 (en) * 2007-10-18 2009-05-27 Bayer Schering Pharma AG Fused imidazoles for cancer treatment
UY31292A1 (es) * 2007-08-14 2009-03-31 Imidazoles biciclicos fusionados
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
MX2012004341A (es) 2009-10-16 2012-10-05 Rib X Pharmaceuticals Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
SI2694510T1 (sl) 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze
CN102796103A (zh) * 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
TWI674263B (zh) 2013-12-19 2019-10-11 瑞士商諾華公司 用於治療寄生蟲疾病之化合物及組合物
HK1249758A1 (zh) 2015-03-11 2018-11-09 Melinta Therapeutics, Inc. 抗微生物化合物及其制备和使用方法
US11098047B2 (en) 2016-05-06 2021-08-24 BioVersys AG Antimicrobials and methods of making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) * 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.

Also Published As

Publication number Publication date
EA009038B1 (ru) 2007-10-26
DE602004010680T2 (de) 2009-01-02
ZA200601706B (en) 2007-09-26
ATE380816T1 (de) 2007-12-15
BRPI0412636A (pt) 2006-09-26
EP1660500A1 (en) 2006-05-31
JP2007500160A (ja) 2007-01-11
WO2005014598A1 (en) 2005-02-17
EA200600330A1 (ru) 2006-08-25
KR20060034303A (ko) 2006-04-21
AU2004263297A1 (en) 2005-02-17
DE602004010680D1 (de) 2008-01-24
US20060189631A1 (en) 2006-08-24
ES2298798T3 (es) 2008-05-16
EP1660500B1 (en) 2007-12-12
CN1860121A (zh) 2006-11-08

Similar Documents

Publication Publication Date Title
EP1660500B1 (en) Substituted imidazopyrimidines for the prevention and treatment of cancer
AU2005205915B2 (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
JP5208962B2 (ja) 二環式ピリミジノンおよびその使用
EP1032575B1 (en) 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
JP5925809B2 (ja) 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用
CN113039182A (zh) Yap/taz-tead相互作用的抑制剂及其在癌症治疗中的用途
CN105164135A (zh) 4-取代的吡咯并二氮杂卓和吡唑并二氮杂卓
US6869956B2 (en) Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
WO2005095419A1 (ja) チアゾロピリミジン誘導体
WO2002060386A2 (en) METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)
AU2002247059A1 (en) Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
US6670365B1 (en) Substituted imidazo 1,2a}azines as selective inhibitors of cox-2
CA2424303A1 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
EP3968991A1 (en) Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
Amin et al. novel class of substituted spiro [quinazoline-2, 1’-cyclohexane] derivatives as effective PPAR-1 inhibitors: molecular modeling, synthesis, cytotoxic and enzyme assay evaluation
MXPA06001262A (en) Substituted imidazopyrimidines for the prevention and treatment of cancer
EP4701635A1 (en) 1,2,4-triazole-3-thione inhibitors of trex2 for use in the treatment of psoriasis, atopic dermatitis or ichthyosis
Palusa et al. Synthesis and evaluation of a series of pyrimidine substituted 1, 3, 4-oxadiazole derivatives as antimicrobial and anti-inflammatory agents
AU2007200555A1 (en) Methods of treating inflammatory and immune diseases using inhibitors of IKappaB kinase (IKK)
MXPA06008303A (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
HK1131615B (en) Bicyclic pyrimidinones and uses thereof
HK1037629B (en) Substituted imidazo [1,2a]azines as selective inhibitors of cox-2
HK1070895B (en) Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-b]pyridazine derivatives
HK1070895A1 (en) Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-b]pyridazine derivatives

Legal Events

Date Code Title Description
FZDE Discontinued